Pharmaceuticals, Biotechnology and Life Sciences
Galapagos has started dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D)…
Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, has announced publication in PLoS One of statistical findings evaluating the clinical scale Charcot-Marie-Tooth Neuropathy Score (CMTNS) for application in Charcot-Marie-Tooth Disease Type 1A (CMT1A).
AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system.
Diplomat Pharmacy has concluded the purchase of a Houston based pharmacy and infusion services specialist Affinity Biotech, which focuses on treating patients with hemophilia.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
Allergan has completed the $2.9 billion purchase of Acelity’s subsidiary LifeCell, adding commercial products to its regenerative medicine portfolio, and LifeCell’s innovative manufacturing capabilities and its R&D operations, based in New Jersey.
Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study of Medivir’s MIV-711 in patients with moderate knee osteoarthritis.
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).